Italia markets closed

KALA BIO, Inc. (0JQ2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
7,98+0,15 (+1,92%)
Alla chiusura: 04:16PM GMT
Schermo intero
Chiusura precedente7,83
Aperto7,83
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno7,82 - 7,98
Intervallo di 52 settimane5,27 - 19,48
Volume498
Media Volume320
CapitalizzazioneN/D
Beta (5 anni mensile)-1,86
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili28 mar 2024 - 30 mar 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 1,910 shares of its common stock to one new employee. The stock options were granted on September 15, 2023. The grant

  • GlobeNewswire

    KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

    ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:

  • GlobeNewswire

    KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    -- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED ---- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases ---- As of June 30, 2023, $59.2 mi